Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
ICARIA-MM Study Updates| Int'l Myeloma Foundation
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
OPTIMISMM Trial - Slideset Download - Clin Onc June 2018 | CCO
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma pts - YouTube
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Trials
![PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/be4724496d6a2bc3c1ce363734069c2dc2a77f30/2-Figure1-1.png "PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar")
PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
FDA approves Sarclisa regimen for adults with advanced multiple myeloma
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial - The Lancet Haematology
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
OncLive - Register Today for our next online broadcast: http://www.onclive.com/link/7700 SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis - Clinical Lymphoma, Myeloma and Leukemia
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
POMALYST® (pomalidomide) Treatment Option
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
